Transforming growth factor-beta in human glomerular injury.
Overexpression of the cytokine transforming growth factor-beta has been identified as the key mediator of chronic progressive kidney fibrosis in experimental and human kidney diseases. The renoprotective effects of angiotensin II blockade and low-protein diets have recently been linked to downregulation of transforming growth factor-beta production. Neutralizing the actions of transforming growth factor-beta by decorin gene therapy appears to be a highly effective new approach in the treatment of renal fibrosis.
Peters
H
H
Division of Nephrology, University of Utah School of Medicine, Salt Lake City 84132, USA.
Noble
N A
NA
Border
W A
WA
D000804:Angiotensin II / Q000037:antagonists & inhibitors; D000818:Animals; D058575:Decorin; D016326:Extracellular Matrix Proteins; D015316:Genetic Therapy; D006801:Humans; D007674:Kidney Diseases / Q000209:etiology / Q000503:physiopathology / Q000628:therapy; D007678:Kidney Glomerulus / Q000293:injuries*; D011509:Proteoglycans / Q000235:genetics / Q000627:therapeutic use; D016212:Transforming Growth Factor beta / Q000037:antagonists & inhibitors / Q000502:physiology*
C546878:DCN protein, human; D058575:Decorin; D016326:Extracellular Matrix Proteins; D011509:Proteoglycans; D016212:Transforming Growth Factor beta; D000804:Angiotensin II